Epigenetic Activation of Pro-angiogenic Signaling Pathways in Human Endothelial Progenitors Increases Vasculogenesis

Sylvain Fraineau,1,2,3,7 Carmen G. Pali,1 Brian McNeill,4 Morten Ritso,1 William C. Shelley,5 Nutan Prasain,5 Alphonse Chu,1 Elodie Vion,1 Kristy Rieck,1 Sharmin Nilufar,1 Theodore J. Perkins,1,6 Michael A. Rudnicki,1,2 David S. Allan,1 Mervin C. Yoder,5 Erik J. Suuronen,2,4 and Marjorie Brand1,2,3,*

1Sprott Center for Stem Cell Research, Regenerative Medicine Program, Ottawa Hospital Research Institute, General Hospital, Mailbox 511, 501 Smyth Road, Ottawa, ON K1H8L6, Canada
2University of Ottawa, Department of Cellular and Molecular Medicine, Ottawa, ON K1H8L6, Canada
3Ottawa Institute of Systems Biology, Ottawa, ON K1H8M5, Canada
4Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, ON K1H8L6, Canada
5Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
6University of Ottawa, Department of Biochemistry, Microbiology, Immunology, Ottawa, ON K1H8L6, Canada
7Present address: Normandie Université, UNIROUEN, INSERM U1096, 76000 Rouen, France
*Correspondence: mbrand@ohri.ca
https://doi.org/10.1016/j.stemcr.2017.09.009

SUMMARY

Human endothelial colony-forming cells (ECFCs) represent a promising source of adult stem cells for vascular repair, yet their regenerative capacity is limited. Here, we set out to understand the molecular mechanism restricting the repair function of ECFCs. We found that key pro-angiogenic pathways are repressed in ECFCs due to the presence of bivalent (H3K27me3/H3K4me3) epigenetic marks, which decreases the cells’ regenerative potential. Importantly, ex vivo treatment with a combination of epigenetic drugs that resolves bivalent marks toward the transcriptionally active H3K4me3 state leads to the simultaneous activation of multiple pro-angiogenic signaling pathways (VEGFR, CXCR4, WNT, NOTCH, SHH). This in turn results in improved capacity of ECFCs to form capillary-like networks in vitro and in vivo. Furthermore, restoration of perfusion is accelerated upon transplantation of drug-treated ECFCs in a model of hindlimb ischemia. Thus, ex vivo treatment with epigenetic drugs increases the vascular repair properties of ECFCs through transient activation of pro-angiogenic signaling pathways.

INTRODUCTION

Human endothelial colony-forming cells (ECFCs) are endothelial progenitors that can be isolated from umbilical cord blood and peripheral blood (Ingram et al., 2004; Lin et al., 2000; Medina et al., 2010) or derived from induced pluripotent stem cells (iPSCs) (Prasain et al., 2014). These highly proliferative cells possess the unique property of forming functional blood vessels in vivo upon transplantation (Au et al., 2008; Melero-Martín et al., 2007; Reinsch et al., 2009; Yoder et al., 2007). This property distinguishes ECFCs from more mature endothelial cells and makes them particularly attractive as a cell therapy for enhanced vascular repair in ischemic diseases such as peripheral arterial disease, ischemic retinopathy, myocardial infarction, or stroke (Cooke and Losordo, 2015; Fadini et al., 2012; Fraineau et al., 2015; Park and Gerecht, 2014; Shantsila et al., 2007). Upon transplantation at sites of ischemic injury, ECFCs incorporate into damaged blood vessels and release pro-angiogenic growth factors to facilitate the repair process, ultimately improving blood perfusion and organ function (Alphonse et al., 2014; Bouvard et al., 2010; Pali et al., 2014; Saif et al., 2010; Schwarz et al., 2012). Furthermore, ECFCs can be used to provide trophic support to other therapeutically relevant cells (Lin et al., 2014). While ECFCs represent promising candidates for cell therapy, it is critical to improve their efficacy in vivo through promoting cell survival and increasing the kinetics of cell migration, homing, differentiation, and secretion of pro-angiogenic factors (Chavakis et al., 2008; Cooke and Losordo, 2015).

Studies in endothelial cells have identified several signal transduction pathways (e.g., CXCR4, VEGF, NOTCH, SHH, and WNT) that coordinate survival, differentiation, arterial/venous specification, and blood-vessel morphogenesis (Carmeliet and Jain, 2011; Herbert and Stainier, 2011; Le Bras et al., 2010). Therefore, a major question is how to activate pro-angiogenic signaling pathways in ECFCs such that we can boost the regenerative function of these cells and increase their survival in vivo post transplantation. Promising results have been obtained through pre-activation of the NOTCH pathway where it was shown that the vascular repair potential of transplanted murine endothelial progenitors is significantly increased if the cells are cultured ex vivo with stromal cells overexpressing the Notch ligand Jag-1 prior to transplantation (Kwon et al., 2008). Furthermore, it was recently found that co-implantation of stromal cells expressing the Notch ligand Dll1 decreases apoptosis and enhances the post-natal vasculogenic capacity of human ECFCs in murine subcutaneous implants (Kim et al., 2015). While activation of the Notch pathway...
Figure 1. Pharmacologic Treatment with a Combination of EZH2 and HDAC Inhibitors Enhances ECFC Migration, Capillary Network Formation, and Resistance to Serum Starvation-Induced Apoptosis

(A) GSK-343 and panobinostat lead to a global decrease in H3K27me2/3 levels and an increase in H3/H4-acetyl levels, respectively, as analyzed by western blot. Molecular masses are indicated in kDa. Total histone H3 and H4 serve as loading controls.

(B) GSK-343 and panobinostat do not affect the overall level of indicated proteins, as analyzed by western blot. Molecular masses are indicated in kDa. Tubulin serves as a loading control.

(C) GSK-343 and panobinostat increase the kinetics of ECFC migration as measured by gap closure assay. Left: representative pictures of ECFCs stained with crystal violet after 10 hr migration (10× magnification; scale bar, 250 μm). Dashed circles represent the gap area prior

(legend continued on next page)
through external stimulation of Notch receptors may provide a valuable strategy to enhance vascular repair properties of endothelial progenitors, several other signaling pathways (e.g., VEGFR, CXCR4, SHH, WNT) are also essential for angiogenesis and post-natal vasculogenesis. However, an approach that simultaneously activates multiple pro-angiogenic pathways in ECFCs is currently lacking.

We previously demonstrated that ex vivo treatment with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) increases ECFC-mediated vascular repair in hindlimb ischemia (Palii et al., 2014), providing proof of principle that the priming of ECFCs with epigenetic drugs prior to transplantation is a valuable strategy to improve their regenerative function (Fraineau et al., 2015). Stem and progenitor cells are characterized by a high prevalence of transcriptionally competent but repressed (i.e., “poised”) genes that are marked by both active (histone H3 lysine 4 trimethylation [H3K4me3]) and repressive (histone H3 lysine 27 trimethylation [H3K27me3]) histone modifications that play important roles in differentiation and development (Benyoucef and Brand, 2015; Voigt et al., 2013). While those bivalent genes are expressed at extremely low levels, it has been proposed that the presence of H3K4me3 may prime them for rapid activation upon removal of H3K27me3. Here, we set out to test the hypothesis that decreasing the levels of the repressive mark H3K27me3 with epigenetic drugs could improve the vascular repair properties of ECFC through activation of pro-angiogenic signaling pathways.

RESULTS

A Combination of Epigenetic Drugs Increases ECFC Migration, Capillary Network Formation, and Resistance to Serum Starvation-Induced Apoptosis

Repressive histone marks H3K27me2/3 are established on chromatin by the polycomb group repressive complex 2 (PRC2), a protein complex comprised of three core sub-units: methyltransferase EZH2 and two other proteins, EED and SUZ12, both of which are required for PRC2 catalytic activity (Di Croce and Helin, 2013). To decrease H3K27me2/3 levels, we treated human umbilical cord blood-derived ECFCs with GSK-343, a potent and selective inhibitor of EZH2 (Verma et al., 2012). As expected, GSK-343 exposure led to a global decrease of H3K27me2/3 levels in a time- and dose-dependent manner (Figures 1A, S1A, and S1B). Importantly, other histone marks, such as H3K27me1, H3K4me3, H3K9me3, H4K20me3, or histone acetylation, are not affected (Figures 1A and S1B). Furthermore, GSK-343 does not lead to a decrease of PRC2 subunits nor does it alter the level of other chromatin-modifying enzymes, including the acetyltransferase P300, the deacetylase HDAC1, the H3K27 demethylase UTX, the H3K9 methyltransferase G9a, or the DNA methyltransferases DNMT1 and DNMT3A (Figure 1B). This is in contrast to the widely used S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin (DZNep), which depletes PRC2 subunits and leads to a global decrease of multiple histone marks, including H3K27me3 H3K4me3 but also H4K20me3, H3K9me3, H3K4me3, and others (Helin and Dhanak, 2013; Miranda et al., 2009; Ohtani et al., 2011; Tan et al., 2007). Thus, in contrast to DZNep, GSK-343 is a potent and selective inhibitor of EZH2 in ECFCs.

Next, we examined the effects of GSK-343 on the capacity of ECFCs to migrate (using a gap closure assay) and to form a capillary-like network on Matrigel. These experiments revealed that GSK-343 significantly improves the pro-angiogenic properties of ECFCs, increasing both the kinetics of cell migration (Figure S1C) and the capacity of ECFCs to form a capillary-like network (Figure S1D) in a dose-dependent manner. Consistent with this, we found that knocking down EZH2 also increases ECFC-mediated capillary network formation (data not shown). Thus, to cell migration. Right: fraction of the gap area invaded by migrating cells at the indicated times. Average from three independent experiments (n = 3) each performed in duplicate are shown ±SEM.

(D) GSK-343 and panobinostat increase ECFC-mediated capillary-like structure formation on Matrigel. Left: representative pictures of capillary-like structures stained with calcein (2.5× magnification; scale bar, 1 mm). Right: total capillary length of the network is expressed as the mean percentage of control values corresponding to cells treated with vehicle ±SEM. Data shown from three independent experiments (n = 3) each performed in duplicate.

(E) GSK-343 and panobinostat do not induce apoptosis in ECFCs as measured by fluorescence-activated cell sorting (FACS) after 7-AAD and annexin V staining.

(F) GSK-343 and panobinostat reduce serum starvation-induced apoptosis in ECFCs as measured by FACS after 7-AAD and annexin V staining. ECFCs were grown in serum-containing EGM-2 medium or serum-depleted EBM-2 medium.

(E and F) Data expressed as mean percentage of control values corresponding to cells treated with vehicle ±SEM from three independent experiments (n = 3), each performed in duplicate.

(G) GSK-343 and panobinostat decrease ECFC proliferation as analyzed by bromodeoxyuridine (BrdU) incorporation. The percentage of cells incorporating BrdU is indicated ±SEM from four independent experiments (n = 4), each performed in duplicate.

***p < 0.001; **p < 0.01; *p < 0.05; ns, non-significant. See also Figures S1 and S2.
Figure 2. Pharmacologic Treatment of ECFCs with a Combination of EZH2 and HDAC Inhibitors Activates Multiple Pro-angiogenic Pathways Simultaneously

(A) Global changes in gene expression upon drug treatment versus vehicle treatment analyzed by RNA-seq. Scatterplot shows upregulated (red) and downregulated (green) genes (n = 3).

(B) Representative Gene Ontology (GO) Biological Process categories significantly enriched for up- and downregulated genes in ECFCs treated with GSK-343 and panobinostat.

(C) Heatmaps of up- and downregulated genes that belong to the indicated signaling pathways as identified by RNA-seq analysis and validated by qRT-PCR (*). Data are expressed in log2(FPKM) (n = 3). The feedback arrow indicates a gene belonging to both receptor and target gene categories.

(legend continued on next page)
inhibition of EZH2 is an efficient strategy to improve the angiogenic properties of ECFCs in vitro.

We showed previously that pre-treatment with the histone deacetylase (HDAC) inhibitor TSA increases ECFC-mediated capillary network formation (Palli et al., 2014). Since GSK-343 has no effect on histone acetylation (Figures 1A and S1B), we hypothesized that combining EZH2 and HDAC inhibitors may further improve ECFC function by acting on complementary epigenetic pathways. To test this hypothesis, we sought to use the highly potent class I, II, and IV HDAC inhibitor panobinostat (LBH589), which is less toxic than TSA and is already clinically approved for cancer treatment (Andreu-Vieyra and Berenson, 2014; Dokmanovic et al., 2007). First, we confirmed that panobinostat used as a single agent is at least as efficient as TSA for improving the pro-angiogenic capacity of ECFCs, increasing both cell migration (Figure S2D) and capillary network formation (Figure S2E). Furthermore, we confirmed that, at the established optimal conditions (i.e., 10 nM for 2 hr), panobinostat leads to a significant increase in the global levels of histone H3 and H4 acetylation without affecting H3K27me3 or other histone modifications (Figures S2A–S2C and 1A). Having established optimal conditions for GSK-343 and panobinostat treatments as single agents, we combined these epigenetic drugs to determine whether we could further improve the pro-angiogenic capacity of ECFCs, using two independently generated ECFC clones from two distinct cord blood donors, identified 553 upregulated genes and 329 downregulated genes (p < 0.05) (Figure 2A). RNA-seq results were confirmed by qRT-PCR for all genes tested (Figures 3A, S4, S5A, and data not shown). Gene ontology (GO) analysis indicates that upregulated genes are enriched in categories related to blood-vessel development, cell motion, cell adhesion, and response to wounding (Figures 2B and S3A), which confirms that the epigenetic drug combination increases the pro-angiogenic properties of ECFCs. In contrast, downregulated genes are enriched in categories related to cell division and proliferation, consistent with the slight decrease in cell proliferation observed upon drug treatment (Figure 1G). See Tables S1 and S2 for a complete list of changing genes and GO categories. Most interestingly, a pathway analysis identified NOTCH and WNT (wingless-type mouse mammary tumor virus integration site) transduction pathways as being significantly enriched for activated genes (Figure S3B). Furthermore, we noticed that three additional pro-angiogenic pathways, CXCR4 (for C-X-C chemokine receptor type 4), VEGFR (for vascular endothelial growth factor receptor), and SHH (for sonic hedgehog), are also activated upon drug treatment (Figure 2C). All five transduction pathways activated by the epigenetic drug combination have previously demonstrated pro-angiogenic roles, with VEGFR being a master regulator of all aspects of angiogenesis and vasculogenesis (including cell survival, proliferation, migration,
Figure 3. Pharmacologic Treatment of ECFCs with a Combination of EZH2 and HDAC Inhibitors Increases Gene Expression through H3K27me3 Demethylation and Histone H3 Acetylation

(A) Transcript levels of indicated genes were measured by qRT-PCR following treatment of ECFCs with vehicle, GSK-343, panobinostat, or GSK-343-panobinostat combination, as indicated. qRT-PCR values are expressed as mean percentages of vehicle-treated cells ±SEM with B2M serving as internal control. (n ≥ 3). ***p < 0.001; *p < 0.05; ns, non-significant.

(B) RNA polymerase II (pol II) binding to indicated gene promoters was assessed by ChIP-qPCR.

(C–E) Enrichment of H3K27me3 (C), H3K4me3 (D), and H3 acetyl (E) histone marks to indicated gene promoters was assessed by ChIP-qPCR.

(B–E) ChIPs were performed using indicated antibodies (Ab) or IgG as a negative control (Mock). qPCR values are expressed as mean fractions of input ±SD.

See also Figure S5.
differential, and morphogenesis), CXCR4 promoting endothelial progenitor cell migration, and homing, while NOTCH, WNT, and SHH pathways play critical roles in regulating vessel formation, branching, and maturation (Carmeliet and Jain, 2011; Chavakis et al., 2008; Dejana, 2010; Herbert and Stainier, 2011; Le Bras et al., 2010; Park et al., 2013). Interestingly, for each signaling pathway, upregulated genes belong to ligands, receptors, and downstream target genes (Figure 2C), which indicates global activation upon drug treatment. For instance, ligands (DKK3, WNT5A, WNT9A, WNT4, and WNT11), receptors (FZD2, FZD1, FZDS, and FZD7), and target genes (TCF7L1, JAG1, MML1, and EGR1) of the WNT pathway are activated (Figure 2C and see Figures S3D and S4 for selected examples). Furthermore, negative regulators of WNT and VEGFR pathways (e.g., DKK1 as well as SEMA3A) are downregulated (Figure 2C). Noticeably, parsing the genes in categories according to their expression levels reveals that the drug combination activates low-to-moderately expressed genes (e.g., CXCL12, FZD7, DLL1, SHH, CXCR4, DLL4), whereas genes that are already expressed at high levels (e.g., the transcription elongation factor gene ELP3 or the endothelial nitric oxide synthase [eNOS] gene NOS3; Chan et al., 2004) are not significantly affected (Figure S3C). Finally, we confirmed activation of the identified pro-angiogenic pathways at the protein level by western blot where we detected increased levels of VEGFR1, VEGFR2, intracellular NOTCH, and CXCR4, as well as increased phosphorylation of VEGFR2, AKT, and ERK1/2 proteins (Figure 2D). Taken together, these results indicate that in ECFCs, pro-angiogenic pathways are maintained in a repressed/poised state. Most importantly, we found that five major pro-angiogenic transduction pathways can be activated simultaneously in endothelial progenitors through ex vivo drug treatment.

**Activation of Pro-angiogenic Pathways by Epigenetic Drugs Occurs through Resolving Bivalently Marked Genes**

To better understand the mechanism of action of panobinostat and GSK-343, we further dissected the effect of these drugs (alone and in combination) on genes representative of various pathways. Interestingly, even though all genes tested are significantly increased upon treatment with the drug combination (validating our RNA-seq results), some genes respond to both drugs in a seemingly additive fashion (e.g., FZD7, KDR, DLL4, HEY2) while others appear to be more responsive to the HDAC inhibitor (e.g., DLL1, SHH) or to the EZH2 inhibitor (e.g., CXCR4, CXCL12, ANGPT2) with ELP3 serving as a control not altered by drug treatment (Figures 3A and S4). These differential effects on gene expression are reflected by differential RNA polymerase II (pol II) binding on gene promoters (Figure 3B). Then, we examined the effects of the drugs (alone and in combination) on histone post-translational modifications (PTMs). Consistent with their highly specific effects on global histone PTMs levels (Figures 1A, S1B, and S2C), we found that both drugs modify their respective targets without affecting other histone PTMs. Specifically, the EZH2 inhibitor GSK-343 decreases the repressive histone mark H3K27me3 on all three representative genes (Figure 3C) with no effect on H3K4me3 (Figure 3D) or H3-Ac (Figure 3E). Similarly, the HDAC inhibitor panobinostat increases histone H3 acetylation on all genes tested (Figure 3E) with no effect on H3K27me3 (Figure 3C) or H3K4me3 (Figure 3D). Taken together, these results indicate that the combination of GSK-343 and panobinostat increases gene expression in ECFCs through a mechanism that entails removal of the repressive histone mark H3K27me3 and increase in the active histone mark H3-Ac.

Interestingly, these experiments also revealed several properties of the genes that respond to the drug combination, including (1) the presence of both active (H3K4me3 and H3-Ac) and repressive (H3K27me3) histone marks on their promoter (Figures 3C, 3D, and 3E); (2) low, but detectable pol II binding on their promoter (Figure 3B); and (3) a low level of expression (Figure S3C). These properties characterize a particular sort of genes named “bivalent” that are maintained in a state of equilibrium between full repression and full activation (Benyoucef and Brand, 2015; Voigt et al., 2013). Even though bivalent genes are found in differentiated cells, they are more prevalent in stem/progenitor cells (e.g., Cui et al., 2009; Karmodiya et al., 2012; Mikkelsen et al., 2007), and they are poised to respond quickly (positively or negatively) to signaling cues from the environment (Benyoucef and Brand, 2015; Voigt et al., 2013). Bivalent genes differ both from highly expressed genes (e.g., ELP3 and NOS3) that are devoid of the repressive mark H3K27me3 (Figures 3 and S5) and from completely repressed genes (e.g., the non-endothelial genes PAX7 and MYOD) that are devoid of the active marks H3K4me3 and H3-Ac and do not display pol II binding (Figure S5).

To better understand the mechanism leading to H3K27me3 removal and H3-Ac increase upon drug treatment, we tested for binding of the epigenetic enzymes responsible for adding/removing these histone modifications. Interestingly, we found that bivalent gene promoters are co-bound by enzymes with antagonistic activities: (1) the H3K27 methyltransferase EZH2 and the H3K27 demethylase UTX, as well as (2) the histone acetyltransferase P300 and the histone deacetylase HDAC1 (Figure 4). Furthermore, these enzymes remain tethered to the
genes upon drug treatment (data not shown). In contrast, EZH2 is not bound to the promoter of the highly expressed ELP3 gene (Figure 4A), consistent with the absence of H3K27me3 at this site (Figure 3C). Taken together, these results suggest that in non-treated ECFCs, EZH2 and UTX compete for methylation/demethylation of H3K27 at bivalent gene promoters, resulting in an enrichment of the repressive histone mark H3K27me3 (Figure 3C) that is sufficient to maintain low levels of gene expression (i.e., poised status) (Figures 3A, 4E, S3C, S3D, and S4). When EZH2 is inhibited (upon GSK-343 treatment), the equilibrium is displaced in favor of UTX, which rapidly removes the repressive mark H3K27me3 (Figure 3C), leading to increased gene transcription (Figures 3A, 4E, S3C, and S3D). A similar mechanism appears to be in place for histone acetylation/deacetylation where P300 and HDAC1 are co-bound to bivalent gene promoters (Figure 4) and compete for histone modification, resulting in increased acetylation upon panobinostat-mediated inhibition of HDAC activity (Figure 3E). Thus, ECFCs maintain specific genes in a repressed/poised state through the recruitment of antagonistic “activating” and “repressive” chromatin-modifying enzymes that establish a bivalent gene promoter status characterized by the presence of both active (H3K4me3 and H3-Ac) and repressive (H3K27me3) histone marks (Figure 4E). Importantly, this poised/bivalent status can be resolved through pharmacologic inhibition of the repressive enzymes EZH2 and HDAC leading to full gene activation.

**Gene Activation Mediated by HDAC and EZH2 Inhibitors Is a Reversible Process**

Co-binding of antagonistic chromatin-modifying enzymes on bivalent gene promoters (Figure 4) predicts that gene activation through pharmacologic inhibition of HDACs and EZH2 will be reversible upon drug removal. To test this hypothesis, ECFCs were treated with a combination of GSK-343 and panobinostat. Then, treated ECFCs were harvested, washed, and re-plated in the absence of the epigenetic drug cocktail. Measuring gene expression and histone PTMs at several time points after re-plating, we observed both increased H3K27me3 and decreased H3-Ac at promoters of pro-angiogenic genes upon drug removal (Figures 5B and 5C). Furthermore, after 24 hr,
the pro-angiogenic genes had reverted back to their native transcriptionally repressed status (Figure 5A). Taken together, these results confirm the transient nature of panobinostat/GSK-343-mediated epigenetic modifications at pro-angiogenic genes in ECFCs.

**Pharmacologic Inhibition of HDAC and EZH2 Increases ECFC-Mediated Vasculogenesis and Improves the Therapeutic Potential of Transplanted ECFCs in a Hindlimb Ischemia Mouse Model**

The results described above revealed that several major pro-angiogenic transduction pathways are activated in ECFCs through pharmacologic inhibition of EZH2 and HDACs. To determine whether these effects translate into increased vasculogenesis in vivo, ECFCs were pretreated with GSK-343 and panobinostat prior to embedding into collagen matrices that were subcutaneously implanted into immunodeficient mice (Prasain et al., 2012). After 3 weeks, implants were harvested and analyzed for blood-vessel formation using a human-specific CD31 antibody as previously described (Prasain et al., 2012). This experiment revealed the formation of ECFC-derived micro-capillaries (Figure 6A) where the presence of surrounding murine smooth muscle cells suggests capillary maturation (Figure S6). Furthermore, the number of these human, ECFC-derived capillaries is significantly increased in implants from drug-treated ECFCs (Figure 6A, right panel), confirming the efficacy of combined GSK-343 and panobinostat treatment in improving ECFC-derived vasculogenesis in vivo.

Finally, we sought to determine the extent to which ex vivo treatment with epigenetic drugs enhances the vascular repair function of ECFCs. To address this question, we used a murine model of hindlimb ischemia (Limbourg et al., 2009; Palii et al., 2014), where ischemia is induced by ligation of the left femoral artery, followed...
Figure 6. Pharmacologic Treatment with a Combination of EZH2 and HDAC Inhibitors Accelerates Vasculogenesis and Blood-Flow Recovery by Transplanted ECFCs in a Mouse Model of Hindlimb Ischemia

(A) H&E staining (left) and anti-human (h) CD31 staining (right) identify ECFCs that have formed micro-capillaries in collagen gels after 3 weeks of implantation in mice (scale bar, 200 μm). Numbers of fully closed ECFC-derived hCD31+ capillaries are indicated per measured explanted area as mean values ± SEM (n = 6 mice per group).

(B) Laser Doppler perfusion imaging was used to measure blood flow pre-operatively (pre-op), immediately after induction of hindlimb ischemia (day 0) and at the indicated time points after injection of ECFCs pretreated with vehicle or with the drug combination. Left: representative laser Doppler images (Isch., Ischemic leg; NI, non-ischemic leg). Right: perfusion ratios (Isch./NI) are indicated as mean values ± SEM (ECFCs: days 0–14, n = 7 mice; days 21–28, n = 3 mice. ECFCs treated: days 0–14, n = 8 mice; days 21–28, n = 4 mice).

(legend continued on next page)
by intramuscular injection of treated or non-treated ECFCs as cell therapy. This experiment revealed that ECFCs pretreated ex vivo with GSK-343 and panobinostat are more rapid at restoring blood flow in the ischemic leg compared with their non-treated counterparts (Figure 6B). Specifically, by measuring blood flow using Doppler analysis at several time points after cell therapy, we found that the kinetics of blood-flow recovery in the ischemic leg is significantly accelerated when GSK-343-panobinostat-treated ECFCs are used for transplantation (Figure 6B).

This improvement is therapeutically relevant given that the speed of blood-flow recovery is one of the most important factors in saving organ function after acute ischemia (Callum and Bradbury, 2000; Creager et al., 2012). Furthermore, the improved perfusion persists for at least 4 weeks post transplantation in mice injected with either drug-treated or non-treated ECFCs (Figure 6B).

Thus, pre-activation of ECFCs with a cocktail of epigenetic drugs (i.e., EZH2 and HDAC inhibitors) administered ex vivo is a promising strategy to increase the therapeutic potential of these cells and boost their vascular repair function in vivo through increased activity of multiple pro-angiogenic signaling pathways (Figure 6C).

**DISCUSSION**

ECFCs are human endothelial progenitor cells with unique capabilities to form vascular structures in several animal models of ischemia (Palli et al., 2014; Prasain et al., 2014). However, these cells have not been fully characterized and additional strategies are needed to improve their therapeutic potential. Here, we show that ECFCs maintain several key pro-angiogenic pathways (i.e., NOTCH, WNT, CXCR4, VEGFR, and SHH) in a repressed/ poised state through the establishment of bivalent gene promoters that are characterized by the simultaneous enrichment of active and repressive histone PTMs. This equilibrium is maintained by epigenetic enzymes with competing activities (i.e., EZH2/UTX and P300/HDAC1) that are co-bound to gene promoters, resulting in low expression levels. In vivo, ECFCs presumably require external signals from the environment to fully activate pro-angiogenic pathways in response to vascular injury. Interestingly, our results indicate that this activation process can be initiated ex vivo prior to transplantation through pharmacologic approaches with specific EZH2 and HDAC inhibitors. Importantly, this ex vivo “boosting” procedure that leads to the activation of multiple pro-angiogenic pathways in ECFCs is translated in vivo by enhanced vasculogenesis, angiogenesis, and accelerated vascular repair in a hindlimb ischemia model. Furthermore, the reversible nature of epigenetic modifications ensures that the injected cells remain responsive to signals from the environment, optimizing vascular repair to the host’s specific needs and limiting potential adverse effects such as blood-vessel overgrowth.

In this study, we have focused on histone modifications enriched on promoters of specific genes that belong to pro-angiogenic pathways. Future studies, using genome-wide approaches, are necessary to identify the full extent of bivalent promoters in ECFCs. Furthermore, bivalent marks have also been identified on distal regulatory elements (Mikkelsen et al., 2007), suggesting that our epigenetic drug cocktail may also affect the epigenetic state of enhancers. A detailed understanding of enhancer/promoter communications in ECFCs, as determined by chromosome conformation capture (3C) approaches (Davies et al., 2017), will be required as a pre-requisite to appreciate the full extent of epigenetic changes occurring upon drug treatment and their consequences on gene expression and vascular repair.

**EXPERIMENTAL PROCEDURES**

*Cell Isolation and Culture*

All procedures were approved by the Ottawa Hospital Research Ethics Board (2007804-01H). Human ECFCs were derived from umbilical cord blood obtained after informed consent from the Canadian Cord Blood for Research Program (2014.007) and cultured as previously described (Palli et al., 2014; Yoder et al., 2007). Briefly, mononuclear cells were isolated by Ficoll density gradient centrifugation and seeded onto CellBIND six-well plates (Corning) at a density of 10^5 mononuclear cells/well in EGM-2 BulletKit medium (Lonza) supplemented with 10% fetal bovine serum. Individual ECFC colonies were re-plated separately and analyzed by flow cytometry (CD31+/CD34+/CD45−) after each passage. All experiments were performed with at least three biologically independent ECFC clones between passage 3 and 6.

*Capillary-like Network Formation Assay*

ECFCs, pretreated with epigenetic drugs or vehicle as indicated, were seeded into 96-well plates previously coated with 50 µL of phenol-red-free, growth factor reduced Matrigel (Corning) at a density of 5,000 cells/well in duplicates. After 24 hr, cells were stained with 5 µg/mL calcein (BD Bioscience) for 5 min at 37°C and photographed using an Axiovert S100 microscope (Zeiss).

(C) EZH2 and HDAC inhibitors upregulate multiple transduction pathways in ECFCs. Schematic representation of cell-signaling molecules and processes that are upregulated (red) or downregulated (green) upon treatment of ECFCs with the GSK-343 and panobinostat combination. **p < 0.01; *p < 0.05. See also Figure S6.
and AxioVision 4.6 software at 2.5× magnification. Total tube length was quantified using AngioQuant software as described (Fraineau et al., 2012).

Cell Migration Assay by Gap Closure
ECFC migration was measured by gap closure assay using the Radius 96-well cell migration assay (Cell Biolabs) according to the manufacturer’s instructions. Briefly, 2 × 10^5 ECFCs, pretreated with epigenetic drugs or vehicle, were seeded into a 96-well plate containing a hydrogel plug and allowed to adhere onto the plate. The plug was removed providing a cell-free area, and cell migration into the gap was monitored by taking pictures every 3 hr using an Axio Observer A1 microscope (Zeiss) and AxioVision 4.6 software at 10× magnification. Once confluent, cells were labeled with crystal violet (Cell Biolabs). The cell-free area was measured using MATLAB software, which provides a simple graphical user interface through which a user can select an image to calculate the area automatically or manually. Automatic segmentation begins with gray-level thresholding of the input image, followed by a series of morphological operations to detect the cell-free area and calculate the area size in pixels.

Serum Starvation and Apoptosis Assay by Annexin V Staining
ECFCs were plated into 6-well plates containing EBM-2 medium without addition of EGM-2 SingleQuots (Lonza) and incubated overnight (16 hr) prior to harvesting and suspension in annexin V binding buffer (BD Pharmingen). Apoptosis was then assessed using the Annexin V PE Apoptosis Detection Kit I (BD Pharmingen) according to the manufacturer’s instructions.

ECFC Transplant in NOD/SCID Mice
Three-dimensional cellularized collagen matrices were prepared as previously described using the Standardized Oligomer Polymerization Kit (GeniPhys, Indiana, USA) (Prasain et al., 2014). Briefly, type I collagen gels (1.5 mg/mL) were prepared on ice, mixed immediately with ECFCs (4 × 10^6 cells/mL) that had been treated (or not) with the epigenetic drug cocktail as indicated, and left to polymerize for 30 min at 37°C in a CO2 incubator prior to the addition of 500 μL of culture medium in the absence of GSK-343 and panobinostat. After 18 hr incubation, cellularized gels were implanted into the flanks of 6- to 12-week-old NOD/SCID mice, as described (Prasain et al., 2012). Surgical procedures were conducted under anesthesia and a constant supply of oxygen. Three weeks after implantation, gels were recovered from animals that had been humanely euthanized per approved IACUC protocol.

Histology was performed using H&E stain and immunohistochemistry using an anti-human CD31 antibody. Briefly, gel explants were formalin fixed, processed, and embedded in paraffin, followed by serial sectioning (4 μm) using a Leica microtome. Paraffin-embedded tissue sections were deparaffinized in xylene and rehydrated through a 100%–70% ethanol gradient. Heat-induced epitope retrieval was performed at 110°C, 12 min with EDTA buffer (pH 9.0), and 3% H2O2 was used to block endogenous peroxidases. Sections were blocked with Background Sniper reagent (BioCare Medical, CA, USA) and incubated with mouse anti-hCD31 Ab (DAKO, clone JC70A) for 1 hr at room temperature (1:2,000 dilution). The MACH4+ DAB detection system was used according to the manufacturer’s instructions (BioCare Medical, CA, USA). ECFC-derived hCD31+ blood vessels were imaged using an Aperio ScanScope XT (Leica Microsystems).

Mouse Model of Hindlimb Ischemia
ECFC-induced vascular repair was assessed using a hindlimb ischemia mouse model as described (Kuraitis et al., 2011; Pali et al., 2014). All procedures were approved by the University of Ottawa Animal Care Committee and performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. Ischemia was induced in the left hindlimb of 8-week-old athymic nude CD1 female mice by ligation of the proximal end of the femoral artery. ECFCs were injected immediately after skin closure. Specifically, 5 × 10^5 ECFCs, pretreated with the drug combination or vehicle as indicated, were re-suspended in 50 μL of PBS and delivered by two equivolumetric injections into the adductor muscle, downstream of the unilateral left hindlimb ligation site, using an insulin syringe. Blood perfusion was monitored pre-operatively, immediately after surgery, and at the indicated days post operation by laser Doppler perfusion imaging (moorLDI2; Moor Instruments). Results are expressed as the ratio of ischemic to non-ischemic hindlimb perfusion. For non-treated ECFCs, seven mice were monitored up to 14 days, three of which were maintained for up to 4 weeks to evaluate the persistence of blood perfusion. For drug-treated ECFCs, eight mice were monitored up to 14 days, four of which were maintained for up to 4 weeks to evaluate the persistence of blood perfusion.

RNA Extraction, Gene Expression Profiling by RNA Sequencing, and Bioinformatics Analysis
For RNA-seq, we used two independent ECFC clones (clone A and clone B) at passage 3 originating from two distinct cord blood samples, as well as clone A at passage 4 (i.e., clone A0). Clones A, A0, and B were treated with epigenetic drugs or vehicle independently of each other, and therefore represent three biological replicates. For each clone, total RNA was extracted from 10^6 ECFCs using the RNaseq Mini Kit (Qiagen), including a genomic DNA digestion step with DNase I (Qiagen), and analyzed by high-throughput sequencing as previously described (Benyoucef et al., 2016).

Chromatin Immunoprecipitation
Analysis of histone modifications was performed by native chromatin immunoprecipitation (ChIP) as described (Brand et al., 2008). Cofactor binding was assessed by crosslink ChIP as described (Pali et al., 2014). ChIPPed DNA was purified by phenol-chloroform extraction, precipitated with ethanol, and specific DNA sequences were amplified with PerfeCTa TaqSYBRGreen SuperMix (Quanta Biosciences) using a Rotor-Gene Q real-time PCR system (QIAGEN). ChIPPed DNA quantity was calculated compared with a genomic DNA standard curve using Rotor-Gene Q Series Software 1.7 (QIAGEN) with R² > 0.96.

Statistical Analyses
Data obtained from at least three independent experiments each in duplicate or triplicate were expressed either as mean values or
percentages of control values ± SD or SEM. When indicated, statistical significance between data groups was determined by non-parametric Kruskal-Wallis test followed by Dunn’s post hoc test, or parametric one- or two-way ANOVA followed by Dunnett or Bonferroni post hoc test using GraphPad Prism 5 software. Use of the non-parametric Kruskal-Wallis test or ANOVA was determined depending on their distribution assessed by the Shapiro-Wilk normality test. Data are considered to be significantly different at p < 0.05. The p values are depicted with asterisks in the figures as follows: ***p < 0.001; **p < 0.01; *p < 0.05; ns, non-significant; ND, non-determined.

ACCESSION NUMBERS
RNA-seq data have been deposited in the public GEO database (GEO: GSE80819).

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, six figures, and two tables and can be found with this article online at https://doi.org/10.1016/j.stemcr.2017.09.009.

AUTHOR CONTRIBUTIONS
S.F. designed and performed most in vitro experiments, prepared cells for ischemia experiments, prepared figures, and contributed to the writing of the manuscript. C.G.P. designed and performed some in vitro experiments, prepared cells for ischemia experiments, and participated in collagen transplant experiments. B.M. designed and performed ischemia experiments under supervision of E.J.S. M.R. designed and performed some immunohistochemistry experiments under supervision of M.A.R. W.C.S. and N.P. designed and performed transplant experiments. K.R. participated in the initial drug screen. S.N. designed a program for analysis of cell migration under supervision of T.J.P. D.S.A. supervised the project. M.B. designed, coordinated, and supervised the project and contributed to the writing of the manuscript. All authors participated in data analyses and figure preparation and provided feedback on the manuscript.

ACKNOWLEDGMENTS
We thank Y. Le, D. Yevstafiev, and C.-P. Chaturvedi (OHRI) for experimental help; S. Lavictoire, I.A.J. Lorimer, A.M. Gagnon, A. Sorisky, and W.L. Stanford (OHRI) for providing antibodies; and E.J. Dilworth (OHRI) for critically reading the manuscript. RNA sequencing was performed at the Institut de Recherches Cliniques de Montréal (Canada). This project was funded with grants from the Canadian Institutes of Health Research (CIHR) (MOP-82813 to M.B.); the Department of Medicine, University of Ottawa (to D.S.A.); and the Heart and Stroke Foundation of Canada (GIA-000225 to E.J.S.). S.F. is supported by a fellowship from the Cushion Fund.

Received: November 5, 2016
Revised: September 11, 2017
Accepted: September 12, 2017
Published: October 12, 2017

REFERENCES


Supplemental Information

Epigenetic Activation of Pro-angiogenic Signaling Pathways in Human Endothelial Progenitors Increases Vasculogenesis

Figure S1 (related to Figure 1): Pharmacologic treatment with the EZH2 inhibitor GSK-343 increases ECFCs migration and capillary-network formation.

(A) Dose-dependent decrease in H3K27me3 levels upon GSK-343 treatment. Left panel: representative Western blot. Molecular masses are indicated in kDa. Right panel: densitometry analysis of H3K27me3.
levels relative to H3 levels. Results are expressed as the percentage of H3K27me3 / total H3 ratio in GSK-343 treated cells relative to vehicle treated cells ± SEM (n=4).

(B) Time-dependent decrease in H3K27me3/2 levels upon GSK-343 treatment analyzed by Western blot. Molecular masses are indicated in kDa.

(C) Dose-dependent increase in the kinetic of ECFC migration upon GSK-343 treatment as measured by gap closure assay. Left panel: representative pictures of ECFCs stained with crystal violet after 10h migration (10X magnification, scale bar 250 µM). Right panel: fraction of the gap area invaded by migrating ECFCs pre-treated for 72h with GSK-343 at the indicated concentrations. Average from 3 independent experiments (n=3) each performed in duplicate are shown ± SEM.

(D) Dose-dependent increase in ECFC-mediated capillary-like structure formation on Matrigel upon GSK-343 treatment. Left panel: representative pictures of capillary-like structures stained with calcein (2.5X magnification, scale bar 1 mm). Right panel: total capillary length of the network is expressed as the mean percentage of control values corresponding to cells treated with vehicle ± SEM. Data shown from 3 independent experiments (n=3) each performed in duplicate.
Figure S2 (related to Figure 1): Pharmacologic treatment with the HDAC inhibitor panobinostat increases ECFCs migration and capillary-network formation.

(A) Dose-dependent increase in H3 acetylation (H3-Ac) levels upon panobinostat treatment. Left panel: representative Western blot. Molecular masses are indicated in kDa. Right panel: densitometry analysis of...
H3-Ac levels relative to H3 levels. Results are expressed as the percentage of H3-Ac / total H3 ratio in panobinostat treated cells relative to vehicle treated cells ± SEM (n=3).

(B) Dose-dependent increase in H4 acetylation (H4-Ac) levels upon panobinostat treatment. Left panel: representative Western blot. Molecular masses are indicated in kDa. Right panel: densitometry analysis of H4-Ac levels relative to H3 levels. Results are expressed as the percentage of H4-Ac / total H4 ratio in panobinostat treated cells relative to vehicle treated cells ± SEM (n=3).

(C) Time-dependent increase in H3 acetylation levels upon panobinostat treatment. Left panel: representative Western blot. Molecular masses are indicated in kDa. Right panel: densitometry analysis of H3-Ac levels relative to H3 levels. Results are expressed as the percentage of H3-Ac / total H3 ratio in panobinostat treated cells relative to vehicle treated cells ± SEM (n=3).

(D) Dose-dependent increase in the kinetic of ECFC migration upon panobinostat treatment as measured by gap closure assay. Trichostatin A (TSA) is used as a positive control (Palii et al., 2014). Left panel: representative pictures of ECFCs stained with crystal violet after 10h migration (10X magnification, scale bar 250 µM). Right panel: fraction of the gap area invaded by migrating ECFCs pre-treated for 2h with panobinostat or TSA at the indicated concentrations. Average from 3 independent experiments (n=3) each performed in duplicate are shown ± SEM.

(E) Optimization of the dose of panobinostat to promote ECFC-mediated capillary-like structure formation on Matrigel. TSA is used as a positive control (Palii et al., 2014). Left panel: representative pictures of capillary-like structures stained with calcein (2.5X magnification, scale bar 1 mm). Right panel: total capillary length of the network is expressed as the mean percentage of control values corresponding to cells treated with vehicle ± SEM. Data shown from 3 independent experiments (n=3) each performed in duplicate.
Figure S3 (related to Figure 2): Pro-angiogenic pathways are activated in ECFCs upon pharmacologic treatment with EZH2 and HDAC inhibitors.

(A) Enrichment map of biological processes that are up- (left panel) or down-regulated (right panel) upon drug treatment. Genes that are significantly up- or down-regulated by RNAseq were subjected to Gene Ontology (GO) analysis. Enriched GO biological processes were visualized using the Enrichment Map.
plugin in Cytoscape. Nodes represent enriched biological processes terms with node-size being proportional to gene set size. Edges represent associations between enriched processes. Functionally related gene-set clusters were manually labeled from the most representative GO biological processes. For a full list of enriched categories, see Table S2.

(B) Representative PANTHER pathways significantly enriched for up-regulated genes in ECFCs treated with GSK-343 and panobinostat. The number of up-regulated genes in each category is shown on the right.

(C) GSK-343-panobinostat combination drug treatment increases preferentially the transcription of low-to-moderately expressed genes. Genes identified as being significantly up-regulated by RNAseq were parsed into 3 classes (Low, Medium and High) as indicated. Representative examples of upregulated genes are shown in each category.

(D) Representative examples of up-regulated genes upon GSK-343-panobinostat treatment, as analyzed by RNA-seq. Normalized reads per million mapped reads were loaded into the University of California Santa Cruz genome browser. Normalized reads in vehicle-treated ECFCs are shown in yellow (n=3). Normalized reads in drug-treated ECFCs are shown in blue (n=3). The green color (merge) appears upon yellow and blue overlap.
Figure S4 (related to Figure 2): Pharmacologic treatment of ECFCs with EZH2 and HDAC inhibitors increases gene expression

Left panels: representative examples of up-regulated genes upon GSK-343-panobinostat treatment, as analyzed by RNA-seq. Normalized reads per million mapped reads were loaded into the University of California Santa Cruz genome browser. Normalized reads in vehicle-treated ECFCs are shown in yellow (n=3). Normalized reads in drug-treated ECFCs are shown in blue (n=3). The green color (merge) appears upon yellow and blue overlap. Right panels: transcript levels of indicated genes were measured by qRT-
PCR following ECFCs treatment with vehicle, GSK-343, panobinostat or GSK-343-panobinostat combination, as indicated. qRT-PCR values are expressed as mean percentages of vehicle-treated cells ± SEM with B2M serving as internal control. (n >= 3).
Figure S5 (related to Figure 3): Pharmacologic treatment of ECFCs with EZH2 and HDAC inhibitors does not change the expression of highly expressed or completely repressed genes.

(A) Transcript levels of indicated genes were measured by qRT-PCR following ECFCs treatment with vehicle, GSK-343, panobinostat or GSK-343-panobinostat combination, as indicated. qRT-PCR values are expressed as mean percentages of vehicle-treated cells ± SEM with B2M serving as internal control. (n >= 3). ns: non-significant.
(B) RNA polymerase II (pol II) binding to indicated gene promoters was assessed by ChIP-qPCR.

(C,D,E) Enrichment of H3K27me3 (C), H3K4me3 (D) and H3 acetyl (E) histone marks to indicated gene promoters was assessed by ChIP-qPCR.

(B,C,D,E) ChIPs were performed using indicated antibodies (Ab) or IgG as a negative control (Mock). qPCR values are expressed as mean fractions of input ± SD.
Figure S6 (related to Figure 6): Mature capillary from drug-treated ECFCs.

Immunocytochemistry identifies mature capillaries from drug-treated ECFCs after three weeks implantation in mice. Representative image of paraffin-embedded section stained with human CD31 (hCD31, red) and alpha smooth muscle actin (α-SMA, green) antibodies. Scale bar 50µm. Depending on the mouse, 25% to 73% of hCD31-positive vessels are also positive for α-SMA.
Supplemental Tables

**Table S1 (related to Figure 2)**

List of genes that are significantly up- or down-regulated upon GSK-343 and panobinostat treatment of ECFCs, as identified by RNA-seq.

**Table S2 (related to Figure 2)**

List of Gene Ontology Biological Processes categories significantly enriched for up- and down-regulated genes in ECFCs treated with GSK-343 and panobinostat.

**Supplemental Experimental Procedures**

**Pharmacologic inhibitors**

The EZH2 inhibitor GSK-343 (Sigma-Aldrich Cat#SML0766) and the HDAC inhibitor panobinostat (LBH-589, Selleck Chemicals Cat#S1030) were dissolved in DMSO and used at indicated concentrations.

**Antibodies**

FACS: anti-CD31-FITC (BD Pharmingen, Cat#555445, 1:100), anti-CD34-PE (BD Pharmingen, Cat#555822, 1:100), anti-CD45-APC (Caltag Laboratories, Cat#MHCD45054, 1:100).

Western blotting: anti-AKT (Cell Signaling, Cat#9272, 1:1000), anti-phospho AKT Ser473 (Cell Signaling, Cat#9271, 1:1000), anti-CXCR4 (Abcam, Cat#ab2074, 1:1000), anti-EED (Abcam, Cat#ab4469, 1:400), anti-ERK 1/2 (Millipore, Cat#06-182, 1:5000), anti-phospho ERK 1/2 Thr202/Tyr204 (Cell Signaling, Cat#9101, 1:1000), anti-EZH2 (Cell Signaling, Cat#3147, 1:1000), anti-NOTCH1-NICD Val1744 (Cell Signaling, Cat#4147, 1:1000), anti-P300 (Santa Cruz, Cat#sc-585, 1:200), anti-pan phospho Ser-Thr/Tyr (AnaSpec, Cat#AS-53775, 1:100), anti-SUZ12 (Santa Cruz, Cat#sc-46264, 1:200), anti-Tubulin (monoclonal antibody from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa, 1:5000), anti-UTX (Bethyl Laboratories, Cat#A302-374A, 1:2000), anti-VEGFR1 C17 (Santa Cruz, Cat#sc-316, 1:200), anti-VEGFR2 (Cell Signaling, Cat#2479, 1:1000), anti-pan histone H3 (Millipore, Cat#ab07-690, 1:20000), anti-pan acetylated histone H3 (Millipore, Cat#ab06-599, 1:1000), anti-H3K4me3 (Abcam, Cat#ab8580, 1:2000), anti-H3K27me1 (Invitrogen, Cat#ab49-1012, 1:1000), anti-H3K27me2 (Diagenode, Cat#C15410046, 1:1000), anti-H3K27me3 (Millipore, Cat#ab07-449, 1:2000), anti-pan histone H4 (Abcam, Cat#ab7311, 1:1000) and anti-pan acetylated histone H4 (Millipore, Cat#ab06-866, 1:1000).

Chromatin Immunoprecipitation: 5 µg of the following antibodies were used, anti-P300 (Santa Cruz, Cat#sc-585), anti-HDAC1 (Abcam, Cat#ab07028), anti-RNA pol II (Millipore, cat#05-623), anti-UTX (Bethyl Laboratories, Cat#A302-374A), anti-UTX 9839P (Seenundun et al., 2010), anti-pan acetylated histone H3 (Millipore, Cat#ab06-599), anti-H3K4me3 (Abcam, Cat#ab8580), anti-H3K27me3 (Millipore, Cat#ab07-449), normal rabbit IgG (Santa Cruz Cat#sc-2027) and normal mouse IgG (Santa Cruz Cat#sc-2025). For UTX ChIP, we used a mixture of anti-UTX (Bethyl Laboratories, Cat#A302-374A) and anti-UTX 9839P (Seenundun et al., 2010). For EZH2 ChIP, we used 2.5 µg of anti-EZH2 (Cell Signaling, Cat#3147).
**Fluorescence-Activated Cell Sorting (FACS) analysis**

Cell surface markers (i.e. CD31, CD34, CD45) were measured by FACS as previously described (Palii et al., 2014). Briefly, $10^5$ cells were labeled for 20 min at room temperature with a mixture of anti-CD31-Fluorescein IsoThioCyanate (FITC), anti-CD34-PhycoErythrin (PE) and anti-CD45-AlloPhycoCyanin (APC) antibodies in PBS containing 2% FBS. After washing, cells were resuspended in PBS containing 2% FBS and analyzed with a BD LSRFortessa cell analyzer (BD Bioscience). 10,000 events were recorded and analyzed with BD FACSDiva software version 8.0 (BD Bioscience).

**Cell proliferation**

ECFCs were treated with epigenetic drugs or vehicle as indicated and grown in EBM-2 medium containing EGM-2 SingleQuots (Lonza). BrdU (10 µM) was added to the medium 24h prior to harvesting, and staining with FITC BrdU Flow kit (BD Pharmingen).

**Gene expression profiling by RNA-Sequencing and bioinformatics analysis**

After RNA extraction, quality control was performed for each mRNA sample with RNA 6000 Nano kit (Agilent) to ensure a RNA Integrity Number (RIN)$\geq$10. Libraries were prepared using TruSeq mRNA enrich RNA library kit (Illumina) and paired-end sequencing was performed on an Illumina HiSeq 2000 sequencer. RNA-seq data were analyzed using Bowtie, TopHat, CuffLinks, and CummeRbund software suite (Trapnell et al., 2012). Briefly, paired-end 50-bp reads were mapped to the hg19 GRCh37 genome (University of California at Santa Cruz) and known hg19 Ensembl transcripts using Bowtie version 2.2.4 (Langmead and Salzberg, 2012) in conjunction with TopHat version 2.0.12 (Trapnell et al., 2009) with default parameters. Transcript assembly, quantification and differential gene expression analyses were performed with CuffLinks version 2.2.1 (Trapnell et al., 2010) using default values. Data were imported and analyzed in R version 3.2.0 (R Core Team, 2015) with the bioconductor package CummeRbund version 2.10.0 (Goff et al., 2013). Genes with corrected p-value < 0.05 were considered to be significant.

Genes significantly up- or down-regulated upon epigenetic combined drug treatment (corrected p-value < 0.05) were submitted to DAVID Gene Ontology Analysis version 6.7 (Huang da et al., 2009a, b). Results from DAVID were imported with the EnrichmentMap plugin(Merico et al., 2010) into Cytoscape version 3.2.1 (Shannon et al., 2003) for visualization.

To generate heat maps, expression values in FPKM for genes within the selected GO Categories were retrieved. Heat maps were generated with Cluster version 3.0 (de Hoon et al., 2004) and JavaTree View version 1.1.6r4 (Saldanha, 2004).

**Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)**

For gene expression analysis by qRT-PCR, 1.5 µg total RNA isolated as previously described was annealed with 500 ng random primers (Invitrogen, Cat#48190-011) for 70°C 10 min followed by holding step at 4°C using Mastercycler®epy gradient S (Eppendorf). Reverse transcription step was performed using 200 U M-MLV reverse transcriptase (Promega) mixed with 40 U RNAse OUT (Invitrogen), M-MLV reverse transcriptase reaction buffer (Promega), and 2 mM final dNTP mix (Invitrogen). Complementary DNA (cDNA) synthesis was carried out at 42°C for 1h followed by 70°C for 10 min cycle and final hold at 4°C using Mastercycler®epy gradient S (Eppendorf). cDNA was diluted 1:4 in nuclease free water before amplification with PerfeCTa®SYBR®Green SuperMix (Quanta Biosciences) using Rotor-Gene Q real-time PCR system (Qiagen). Absolute abundance of genes relative to B2M housekeeping gene expression
was calculated based on a cDNA standard curve using Rotor-Gene Q Series Software 1.7 (Qiagen) with R² > 0.96.

**Protein extraction and Immunoprecipitation**

Cells were lysed in protein extraction buffer (Tris HCl 10 mM; NaCl 150 mM; Triton X100 1%; NP40 0.5%; EDTA 1 mM; EGTA 1 mM; Sodium orthovanadate 100 mM; pH7.4) supplemented with protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail 2 (SIGMA) for 5 min on ice before centrifugation at 14,000 rpm for 10 min at 4°C to remove cellular debris.

VEGFR2 immunoprecipitation was performed using 250 µg of whole cell protein lysate incubated overnight at 4°C with 400 ng of anti-VEGFR2 antibody (Cell Signaling) pre-bound to Dynabeads® Protein A (Thermo Fisher Scientific). After several washes with protein extraction buffer, proteins were eluted by two successive heating steps at 95°C for 5 min in Laemmli buffer (Tris-HCl 60 mM pH6.8; SDS 2%; β-mercaptoethanol 5%; Glycerol 10%; Bromophenol blue 0.01%).

For histone extraction, nuclei were first purified using Triton Extraction Buffer (TEB: PBS containing 0.5% Triton X 100 (v/v); 2 mM phenylmethlysulfonyl fluoride (PMSF), 0.02% (w/v) NaN₃) supplemented with protease inhibitor cocktail. Histones were then extracted overnight in 0.2 N HCl at 4°C. Total amount of proteins was measured using BioRad protein Assay (Biorad).

**Immunocytochemistry**

Immunocytochemistry was performed on paraffin embedded sections that were rehydrated in xylene and 100-50% ethanol gradient. Antigen retrieval was performed at 95°C, 15min with 10mM sodium citrate buffer at pH6.0 supplemented with 0.05% Tween-20. Slides were blocked with 2% BSA 5% goat serum 0.1% Tween-20 in TBS for 30min and primary antibodies bound overnight at 4°C in blocking solution – CD31 (Dako, clone JC70A) and alpha-smooth muscle actin (Abcam, ab5694). Secondary antibodies were bound at room temperature in blocking solution – goat anti-rabbit Alexa488 (ThermoFisher, A-11008) and goat anti-mouse IgG1 Alexa546 (ThermoFisher, A-21123). Slides were mounted with PermaFluor containing 1µg/ml Hoechst 33342 and visualized on an AxioObserver.Z1 microscope with an Apochromat 63x/1.40 objective.

**qRT-PCR primers**

<table>
<thead>
<tr>
<th>Gene and location</th>
<th>Primer sense</th>
<th>Primer sequence (5' &gt; 3')</th>
<th>Amplicon size</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANGPT2</strong>&lt;br&gt;NM_001147</td>
<td>Forward</td>
<td>ATTCAGCGACGTGAGGATGGCA</td>
<td>139 bp</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GCACATAGCGTTGCTTAGTC</td>
<td></td>
</tr>
<tr>
<td><strong>B2M</strong>&lt;br&gt;NM_004048</td>
<td>Forward</td>
<td>CACAGCCAAGAGATGTAAGT</td>
<td>268 bp</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CCAGCCCTCTAGAGC</td>
<td></td>
</tr>
<tr>
<td><strong>CXCL12</strong>&lt;br&gt;NM_199168</td>
<td>Forward</td>
<td>GCATCTCAAATTCTCAACCTCC</td>
<td>89 bp</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TCGGGTCAATGACACTTG</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Forward</td>
<td>Reverse</td>
<td>Length</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>-------------</td>
<td>--------</td>
</tr>
<tr>
<td>CXCR4</td>
<td>TGGCATTGTGGGCAATGGATTGGT</td>
<td>TACCAGTTTGGCCACCGCATCAACT</td>
<td>156 bp</td>
</tr>
<tr>
<td>DLL1</td>
<td>TGCTGGATGTGATGACGACGA</td>
<td>ACAGCCTGGATAGCGAGCACAC</td>
<td>110 bp</td>
</tr>
<tr>
<td>DLL4</td>
<td>CCCTGGCAATGTACTGATGCTGAT</td>
<td>TGATGGGTCAGTGATGCTGAG</td>
<td>74 bp</td>
</tr>
<tr>
<td>ELP3</td>
<td>TTGGCCCTCTACGATGCAAAGT</td>
<td>ACACTCCCATACACATGCAGCTTT</td>
<td>100 bp</td>
</tr>
<tr>
<td>FZD7</td>
<td>GCCGCTTCTACACGACT</td>
<td>CCACTCCCATACACATGCAGCTCTTC</td>
<td>54 bp</td>
</tr>
<tr>
<td>HEY2</td>
<td>TGAGAAGACTTGTGCACTGCT</td>
<td>CCCTGGCTTGGCGCATCTTC</td>
<td>110 bp</td>
</tr>
<tr>
<td>KDR</td>
<td>CACCACCTAAACGCCTGACATGTA</td>
<td>GCTCGTGGGCAGCTGTCAT</td>
<td>95 bp</td>
</tr>
<tr>
<td>NOS3</td>
<td>GAAGGCCGACAATCCCTGATGCG</td>
<td>TGATGGGTCAGTGATGCTGAG</td>
<td>135 bp</td>
</tr>
<tr>
<td>PAX7</td>
<td>ACCCCTGCTACACACAT</td>
<td>GAAGGCCGACAATCCCTGATGCG</td>
<td>119 bp</td>
</tr>
<tr>
<td>SHH</td>
<td>CCGAGCGATTGAAGGAACCTACC</td>
<td>AGCTCGTCACTTGGTACACACCTAC</td>
<td>116 bp</td>
</tr>
</tbody>
</table>
ChIP-qPCR primers

<table>
<thead>
<tr>
<th>Gene and location</th>
<th>Primer sense</th>
<th>Primer sequence (5’ &gt; 3’)</th>
<th>Amplicon size</th>
</tr>
</thead>
<tbody>
<tr>
<td>CXCR4 promoter</td>
<td>Forward</td>
<td>CAGTAGAGACACTGAGGCC</td>
<td>93 bp</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TTGAAGCTTGGCCCTACTTT</td>
<td></td>
</tr>
<tr>
<td>DLL1 promoter</td>
<td>Forward</td>
<td>GCATGGCTAATGAGATGCAA</td>
<td>88 bp</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CATTGAGAGGAGGTTTGGGA</td>
<td></td>
</tr>
<tr>
<td>ELP3 promoter</td>
<td>Forward</td>
<td>CCCAGGTCGAGCTTTCATAACC</td>
<td>70 bp</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GGGTCTCAGGGATGGAGGAT</td>
<td></td>
</tr>
<tr>
<td>FZD7 promoter</td>
<td>Forward</td>
<td>GCCAATCAGAAACGCTACC</td>
<td>132 bp</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GCAACCATTGGATCCTCCAT</td>
<td></td>
</tr>
<tr>
<td>MYOD1 promoter</td>
<td>Forward</td>
<td>CCCTCTTTTCACGGTCTCACT</td>
<td>94 bp</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GGTTAGAGCGGCTGTAGAAA</td>
<td></td>
</tr>
<tr>
<td>NOS3 promoter</td>
<td>Forward</td>
<td>GTGGAGCTGAGGCTTAGAGC</td>
<td>141 bp</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TTTCCCTAGGAAGGGGAGGGG</td>
<td></td>
</tr>
<tr>
<td>PAX7 promoter</td>
<td>Forward</td>
<td>GGAACCTGGAAGGAGGAGGAAG</td>
<td>74 bp</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TATCTGTTCCAGGGCTTTGG</td>
<td></td>
</tr>
</tbody>
</table>

**Supplemental References**

R Core Team (2015). R: A Language and Environment for Statistical Computing (Vienna, Austria).